{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:59:15Z","timestamp":1781020755364,"version":"3.54.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005954","name":"Children\u2019s Cancer Foundation","doi-asserted-by":"publisher","award":["HKCH-RFP-2021-002"],"award-info":[{"award-number":["HKCH-RFP-2021-002"]}],"id":[{"id":"10.13039\/501100005954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcyt.2026.102885","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T17:39:55Z","timestamp":1776015595000},"page":"102885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quadruple immunotherapy with allogeneic natural killer cell infusion for recurrent neuroblastoma"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-4179","authenticated-orcid":false,"given":"Chi Hang","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6800-5855","authenticated-orcid":false,"given":"Man Yan","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4178-2777","authenticated-orcid":false,"given":"Wilson Yau Ki","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Pak Yin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Tak Loi","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason Chi Chiu","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela Pui Wah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-3528","authenticated-orcid":false,"given":"Daniel Ka Leung","family":"Cheuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godfrey Chi Fung","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.jcyt.2026.102885_bib0001","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMra0804577","article-title":"Recent Advances in Neuroblastoma","volume":"362","author":"Maris","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jcyt.2026.102885_bib0002","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1200\/JCO.2010.34.3392","article-title":"Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project","volume":"29","author":"London","year":"2011","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.jcyt.2026.102885_bib0003","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102885_bib0004","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/JCO.21.01375","article-title":"Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A","volume":"40","author":"Furman","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102885_bib0005","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1158\/1078-0432.CCR-24-3427","article-title":"A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission","volume":"31","author":"Kushner","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102885_bib0006","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/ni0102-6","article-title":"What is a natural killer cell?","volume":"3","author":"Moretta","year":"2002","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102885_bib0007","doi-asserted-by":"crossref","first-page":"644","DOI":"10.4049\/jimmunol.172.1.644","article-title":"Determinants of Antileukemia Effects of Allogeneic NK Cells","volume":"172","author":"Leung","year":"2004","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102885_bib0008","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.bjc.6603913","article-title":"Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma","volume":"97","author":"Leung","year":"2007","journal-title":"Br J Cancer"},{"issue":"23","key":"10.1016\/j.jcyt.2026.102885_bib0009","doi-asserted-by":"crossref","first-page":"7330","DOI":"10.1158\/1078-0432.CCR-09-1720","article-title":"KIR and HLA Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma","volume":"15","author":"Venstrom","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.jcyt.2026.102885_bib0010","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1158\/0008-5472.CAN-10-2211","article-title":"Genotypes of NK Cell KIR Receptors, Their Ligands, and Fc\u03b3 Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy","volume":"70","author":"Delgado","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102885_bib0011","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","article-title":"NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front Immunol"},{"issue":"21","key":"10.1016\/j.jcyt.2026.102885_bib0012","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1158\/1078-0432.CCR-17-0379","article-title":"A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent\/Refractory Neuroblastoma","volume":"23","author":"Federico","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102885_bib0013","article-title":"Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study","volume":"7","author":"Modak","year":"2018","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102885_bib0014","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1158\/0008-5472.CAN-12-3322","article-title":"Ex Vivo Activation of CD56+ Immune Cells That Eradicate Neuroblastoma","volume":"73","author":"Rujkijyanont","year":"2013","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.jcyt.2026.102885_bib0015","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1084\/jem.20122292","article-title":"Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXR\u03b3 activation","volume":"210","author":"Leung","year":"2013","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102885_bib0016","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1172\/JCI116161","article-title":"Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2","volume":"91","author":"Caligiuri","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2026.102885_bib0017","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fphar.2012.00091","article-title":"Increasing the Clinical Efficacy of NK and Antibody-Mediated Cancer Immunotherapy: Potential Predictors of Successful Clinical Outcome Based on Observations in High-Risk Neuroblastoma","volume":"3","author":"Koehn","year":"2012","journal-title":"Front Pharmacol"},{"issue":"13","key":"10.1016\/j.jcyt.2026.102885_bib0018","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1158\/1078-0432.CCR-13-1766","article-title":"Infusions of Allogeneic Natural Killer Cells as Cancer Therapy","volume":"20","author":"Leung","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.jcyt.2026.102885_bib0019","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1016\/j.bbmt.2017.07.011","volume":"23","author":"Talleur","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102885_bib0020","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1115178","article-title":"Advances in clinical NK cell studies: Donor selection, manufacturing and quality control","volume":"5","author":"Koehl","year":"2016","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.jcyt.2026.102885_bib0021","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1235108","article-title":"Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18\/CHO show higher ADCC levels and improved event-free survival","volume":"5","author":"Siebert","year":"2016","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102885_bib0022","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"158","key":"10.1016\/j.jcyt.2026.102885_bib0023","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable Inference, the Law of Succession, and Statistical Inference","volume":"22","author":"Wilson","year":"1927","journal-title":"J Am Stat Assoc"},{"issue":"17","key":"10.1016\/j.jcyt.2026.102885_bib0024","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.22.01630","article-title":"Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I\/II Trial","volume":"41","author":"Flaadt","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jcyt.2026.102885_bib0025","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1038\/s41591-025-03874-6","article-title":"GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial","volume":"31","author":"Locatelli","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102885_bib0026","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41591-025-03513-0","article-title":"Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma","volume":"31","author":"Li","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jcyt.2026.102885_bib0027","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1593\/neo.04316","article-title":"Downregulation and\/or Release of NKG2D Ligands as Immune Evasion Strategy of Human Neuroblastoma","volume":"6","author":"Raffaghello","year":"2004","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102885_bib0028","article-title":"The immune cell atlas of human neuroblastoma","volume":"3","author":"Verhoeven","year":"2022","journal-title":"Cell Rep Med"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102885_bib0029","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccell.2023.12.008","article-title":"Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy","volume":"42","author":"Wienke","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102885_bib0030","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.22.02875","article-title":"Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons","volume":"42","author":"Oesterheld","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8085","key":"10.1016\/j.jcyt.2026.102885_bib0031","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-025-09564-0","article-title":"Reprogramming neuroblastoma by diet-enhanced polyamine depletion","volume":"646","author":"Cherkaoui","year":"2025","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102885_bib0032","doi-asserted-by":"crossref","DOI":"10.1038\/srep37046","article-title":"Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer","volume":"6","author":"Janakiram","year":"2016","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102885_bib0033","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/CJI.0000000000000379","article-title":"Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockade","volume":"44","author":"Dryja","year":"2021","journal-title":"J Immunother"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102885_bib0034","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102885_bib0035","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/pbc.25555","article-title":"Natural killer cell therapy in children with relapsed leukemia","volume":"62","author":"Rubnitz","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102885_bib0036","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000176","article-title":"Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial","volume":"8","author":"Nguyen","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"24","key":"10.1016\/j.jcyt.2026.102885_bib0037","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2009.27.5016","article-title":"Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children\u2019s Oncology Group Study","volume":"28","author":"London","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102885_bib0038","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1158\/1078-0432.CCR-20-3909","article-title":"Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032","volume":"27","author":"Yu","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"35","key":"10.1016\/j.jcyt.2026.102885_bib0039","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.21.02478","article-title":"Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children\u2019s Oncology Group","volume":"40","author":"Desai","year":"2022","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.jcyt.2026.102885_bib0040","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.3390\/cancers17172723","article-title":"Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed\/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison","volume":"17","author":"Lode","year":"2025","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102885_bib0041","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70165","article-title":"A pilot study of chemoimmunotherapy in the postconsolidation setting for high-risk neuroblastoma (ANBL19P1): A report from the Children\u2019s Oncology Group","volume":"132","author":"Desai","year":"2026","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jcyt.2026.102885_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002267","volume":"9","author":"Chu","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"15","key":"10.1016\/j.jcyt.2026.102885_bib0043","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-21-1356","article-title":"Immunotherapy of Neuroblastoma: Facts and Hopes","volume":"28","author":"Anderson","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jcyt.2026.102885_bib0044","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/pbc.24351","article-title":"131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma","volume":"60","author":"French","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.jcyt.2026.102885_bib0045","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.ijrobp.2018.01.008","article-title":"Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?","volume":"100","author":"Casey","year":"2018","journal-title":"Int J Radiat Oncol"},{"issue":"22","key":"10.1016\/j.jcyt.2026.102885_bib0046","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO-24-02612","article-title":"Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab \u00b1 Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial","volume":"43","author":"Cash","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926008467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926008467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:19:34Z","timestamp":1781018374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926008467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1465324926008467"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102885","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quadruple immunotherapy with allogeneic natural killer cell infusion for recurrent neuroblastoma","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102885"}}